MetaCap

Aytu BioPharma (AYTU) vs NextCure (NXTC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aytu BioPharma (AYTU) has outperformed NextCure (NXTC) over the past year, gaining 32.3% versus a loss of 38.6%. Over five years, NXTC leads with a -91.1% price change compared with -93.2% for AYTU. NextCure is the larger company by market cap ($29.5 million vs $28.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AYTU+32.34%NXTC-38.63%
+51%-20%-91%
Nov 21, 20251 yearNov 20, 2026
AYTU-93.42%NXTC-90.73%
+12%-46%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AYTU versus NXTC key metrics
MetricAYTUNXTC
Share price$2.66$6.45
Market cap$28.91M$29.53M
1-day change0.00%-4.87%
YTD return+2.31%-54.55%
1-year return+32.34%-38.63%
5-year return-93.21%-91.07%
Forward P/E17.16—
EPS (TTM)$-1.78$-6.78
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$57.57M—
Revenue growth (YoY)-13.27%—
Net income (latest FY)$-14.25M$-55.84M
Gross margin63.95%—
Operating margin-14.44%—
Net margin-24.76%—
52-week high$3.07$15.74
52-week low$1.75$1.55
Distance from 52-week high-13.36%-59.02%
Analyst consensusstrong_buynone
Avg. price target upside+263.53%+210.08%
Average volume141.18K79.46K
Shares outstanding10.87M4.58M
Employees7540
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AYTU has outperformed NXTC by 71.0 percentage points over the past year.

About Aytu BioPharma

AYTU stock →

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

About NextCure

NXTC stock →

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees

AYTU vs NXTC FAQ

Which is bigger, Aytu BioPharma or NextCure?

NextCure (NXTC) is larger, with a market capitalization of $29.53M compared with $28.91M for Aytu BioPharma (AYTU).

Which stock has performed better over the past year, AYTU or NXTC?

AYTU returned +32.34% over the past 12 months, compared with -38.63% for NXTC (price return, excluding dividends). Past performance does not predict future results.

Are Aytu BioPharma and NextCure in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons